Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Immunology
Facteur d'impact: 1.352 Facteur d'impact sur 5 ans: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimer: 1040-8401
ISSN En ligne: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2018026335
pages 453-470

IL-33 in Tumor Immunity: Nothing to Sneeze At

Donye Dominguez
Robert H. Lurie Comprehensive Cancer Center, Department of Medicine–Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Yi Zhang
Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Bin Zhang
Robert H. Lurie Comprehensive Cancer Center, Department of Medicine–Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

RÉSUMÉ

Although immunotherapy has been at the forefront of cancer therapy for the last several years, better clinical responses are still desired. Interleukin-33 is perhaps one of the most overlooked antitumor cytokines. Its ability to promote type 1 immune responses, which control tumor growth in preclinical animal models is overshadowed by its association with type 2 immunity and poor prognosis in some human cancers. Accumulating evidence shows that IL-33 is a powerful new tool for restoring and enhancing the body's natural antitumor immunity cycle. Furthermore, the antitumor mechanisms of IL-33 are two-fold, as it can directly boost CD8+ T cell function and restore dendritic cell dysfunction in vivo. Mechanistic studies have identified a novel pathway induced by IL-33 and its receptor ST2 in which dendritic cells avoid dysfunction and retain cross-priming abilities in tumor-bearing conditions. Here, we also comment on IL-33 data in human cancers and explore the idea that endogenous IL-33 may not deserve its reputation for promoting tumor growth. In fact, tumors may hijack the IL-33/ST2 axis to avoid immune surveillance and escape antitumor immunity.


Articles with similar content:

A CCL2-Based Fusokine as a Novel Biopharmaceutical for the Treatment of CCR2-Driven Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.30, 2010, issue 5
Jacques Galipeau, Moutih Rafei
Tolerance and Cancer: A Critical Issue in Tumor Immunology
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 5-6
Hyam I. Levitsky, Eduardo M. Sotomayor, Ivan Borrello
Tumor Plasticity Interferes with Anti-Tumor Immunity
Critical Reviews™ in Immunology, Vol.34, 2014, issue 2
Andres Tittarelli, Salem Chouaib, Jean Paul Thiery, Bassam Janji, Alexander Eggermont
Signal Integration Following Toll-like Receptor Triggering
Critical Reviews™ in Immunology, Vol.22, 2002, issue 3
Alexander Dalpke, Klaus Heeg
CD40 Signaling to the Rescue: A CD8 Exhaustion Perspective in Chronic Infectious Diseases
Critical Reviews™ in Immunology, Vol.33, 2013, issue 4
Dustin A. Cobb, Imtiaz A. Khan, Rajarshi Bhadra